Trial Profile
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (Ages 10 to 17 Years, Inclusive) With Type 2 Diabetes Mellitus
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary) ; Insulin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms MK-8835-059; MK-8835/PF-04971729
- Sponsors Merck Sharp & Dohme Corp.
- 19 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2022 This trial has been discontinued in France according to European Clinical Trials Database record.
- 16 Jun 2022 This trial has been discontinued in France according to European Clinical Trials Database record.